Conference
IXEKIZUMAB IMPROVES PATIENT-REPORTED OUTCOMES THROUGH 52 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TUMOR NECROSIS FACTOR-INHIBITORS
Authors
Kavanaugh A; Marzo-Ortega H; Vender R; Birt J; Adams D; Benichou O; Lin C-Y; Nash P
Volume
48
Pagination
pp. 39-40
Publisher
WILEY
Publication Date
May 1, 2018
Conference proceedings
INTERNAL MEDICINE JOURNAL
ISSN
1444-0903